Kairos Pharma (KAPA) EBIAT (2024 - 2025)
Kairos Pharma (KAPA) has disclosed EBIAT for 2 consecutive years, with -$1.4 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, EBIAT fell 462.06% year-over-year to -$1.4 million, compared with a TTM value of -$4.7 million through Jun 2025, changed N/A, and an annual FY2024 reading of -$2.6 million, down 43.65% over the prior year.
- EBIAT was -$1.4 million for Q2 2025 at Kairos Pharma, down from -$1.3 million in the prior quarter.
- Across five years, EBIAT topped out at -$253000.0 in Q2 2024 and bottomed at -$1.4 million in Q2 2025.